The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC) is associated with marked fibrosis and stromal myofibroblasts, but their functional contribution remains unknown. Transgenic mice with the ability to delete αSMA(+) myofibroblasts in pancreatic cancer were generated. Depletion starting at either noninvasive precursor (pancreatic intraepithelial neoplasia) or the PDAC stage led to invasive, undifferentiated tumors with enhanced hypoxia, epithelial-to-mesenchymal transition, and cancer stem cells, with diminished animal survival. In PDAC patients, fewer myofibroblasts in their tumors also correlated with reduced survival. Suppressed immune surveillance with increased CD4(+)Foxp3(+) Tregs was observed in myofibroblast-depleted mouse tumors. Although myofibroblast-depleted tumors did not respond to gemcitabine, anti-CTLA4 immunotherapy reversed disease acceleration and prolonged animal survival. This study underscores the need for caution in targeting carcinoma-associated fibroblasts in PDAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“subsequent preclinical studies that suppressed in the long term the CAF subset known to be Hedgehog responsive also demonstrated more rapid PDAC progression35,36.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“preclinical studies suggesting that the non-specific targeting or deletion of stromal fibroblasts may not enhance tumour control35,36.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [36]
In the citing paper
“depletion of stromal fibroblasts through hedgehog inhibition, epithelial sonic hedgehog deletion, stromal ablation, or inhibition of lysyl oxidase like-2 increases tumor access to the blood supply and facilitates metastasis, having deleterious consequences on natural history of the disease159–162”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [159]
In the citing paper
“Subsequently, attempts to inactivate CAFs through sonic hedgehog inhibition proved ineffective in patients289, and preclinical studies that were conducted after the fact pinpointed reasons for this failure159,290.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [159]
In the citing paper
“However, inactivation of TGF-β signaling in stromal fibroblasts potentiates neoplasia in adjacent epithelia245.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [245]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Self-citationThe Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M. W., Reinhard, F., Zhang, C. C., Shipitsin, M. V., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,839
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“The desmoplastic reaction is thought to represent a host defense mechanism, similar to wound healing and tissue regeneration, to repair or hopefully impede the conversion of a neoplastic lesion into invasive carcinoma (Bissell and Radisky, 2001; Dvorak, 1986; Lu et al., 2012).”
Bioinformatics and Computational Biology Solutions Using R and Bioconductor
Gentleman, R. C., Carey, V. J., Huber, W. K., Irizarry, R. A., & Dudoit, S. (2005) · Statistics in the health sciences · doi:10.1007/0-387-29362-0 · Cited by 3,470
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–129 of 129
Truong, L.-H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13195028 · Cited by 102
Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming
Velez-Delgado, A., Donahue, K. L., Brown, K. L., Du, W., Irizarry-Negron, V., Menjivar, R. E., Lasse Opsahl, E. L., Steele, N. G., The, S., Lazarus, J., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.016 · Cited by 91
Arwert, E. N., Milford, E. L., Rullan, A., Derzsi, S., Hooper, S., Kato, T., Mansfield, D., Melcher, A., Harrington, K. J., & Sahai, E. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0527-7 · Cited by 90
Shaashua, L., Ben-Shmuel, A., Pevsner-Fischer, M., Friedman, G., Levi-Galibov, O., Nandakumar, S., Barki, D., Nevo, R., Brown, L. E., Zhang, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34081-3 · Cited by 79
Nanoparticle-based hyperthermia, a local treatment modulating the tumor extracellular matrix
Kolosnjaj-Tabi, J., Marangon, I., Nicolas-Boluda, A., Silva, A. K. A., & Gazeau, F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.010 · Cited by 86
Targeting TGFβR2‐mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer
Huang, H., Zhang, Y., Gallegos, V., Sorrelle, N., Zaid, M. M., Toombs, J., Du, W., Wright, S., Hagopian, M., Wang, Z., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910515 · Cited by 87
“…Molecular Medicine 11: e10515 | 2019 11 of 20 12 of 20 EMBO Molecular Medicine 11: e10515 | 2019 ª 2019 The Authors found that myofibroblasts did not induce IL-6 in response to TGFb or IL-1 (Fig 3F), supporting that this CAF population is tumor suppressive (Ozdemir et al, 2014; Rhim et al, 2014).”
BackgroundCancer‐Associated Fibroblasts Suppress Cancer Development: The Other Side of the Coin
Wang, Z., Yang, Q., Tan, Y., Tang, Y., Ye, J., Yuan, B., & Yu, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.613534 · Cited by 81
Xiong, J., Xiao, R., Zhao, J., Zhao, Q., Luo, M., Li, F., Zhang, W., & Wu, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04810-3 · Cited by 79
Fibroblasts as Modulators of Local and Systemic Cancer Metabolism
Sanford-Crane, H., Abrego, J., & Sherman, M. H. (2019) · Cancers · doi:10.3390/cancers11050619 · Cited by 77
Malik, R., Luong, T., Cao, X., Han, B., Shah, N., Franco-Barraza, J., Han, L., Shenoy, V. B., Lelkes, P. I., & Cukierman, E. (2019) · Matrix Biology · doi:10.1016/j.matbio.2018.11.001 · Cited by 74
Zhao, X., Pan, J., Li, W., Yang, W., Qin, L., & Pan, Y. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s176928 · Cited by 75
Kalluri, V. S., Smaglo, B. G., Mahadevan, K. K., Kirtley, M. L., McAndrews, K. M., Mendt, M., Yang, S., Maldonado, A. S., Sugimoto, H., Salvatierra, M. E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63718-2 · Cited by 70
Self-citationA microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment
Geyer, M., Schreyer, D., Gaul, L.-M., Pfeffer, S., Pilarsky, C., & Queiroz, K. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01334-z · Cited by 61
Glutamine deprivation triggers NAGK-dependent hexosamine salvage
Campbell, S., Mesaros, C., Izzo, L., Affronti, H., Noji, M., Schaffer, B. E., Tsang, T., Sun, K., Trefely, S., Kruijning, S., et al. (2021) · eLife · doi:10.7554/elife.62644 · Cited by 58
Han, B., Qu, C., Park, K., Konieczny, S. F., & Korc, M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.003 · Cited by 53
Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer
Lei, F., Xi, X., Batra, S. K., & Bronich, T. K. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255786 · Cited by 51
Deng, L., Jiang, N., Zeng, J., Wang, Y., & Cui, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.733270 · Cited by 51
Fibroblasts in liver cancer: functions and therapeutic translation
Affo, S., Filliol, A., Gores, G. J., & Schwabe, R. F. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00111-5 · Cited by 49
Shinkawa, T., Ohuchida, K., Mochida, Y., Sakihama, K., Iwamoto, C., Abe, T., Ideno, N., Mizuuchi, Y., Shindo, K., Ikenaga, N., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02301-9 · Cited by 41
Immunotherapies for pediatric cancer: current landscape and future perspectives
Hutzen, B., Paudel, S. N., Naeimi Kararoudi, M., Cassady, K. A., Lee, D. A., & Cripe, T. P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09819-z · Cited by 44
Ruggeri, J. M., Franco-Barraza, J., Sohail, A., Zhang, Y., Long, D., Pasca di Magliano, M., Cukierman, E., Fridman, R., & Crawford, H. C. (2020) · The American Journal of Pathology · doi:10.1016/j.ajpath.2020.03.020 · Cited by 40
Leveraging microenvironmental synthetic lethalities to treat cancer
Metcalf, K. J., Alazzeh, A., Werb, Z., & Weaver, V. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143765 · Cited by 42
Perspectives on Hypoxia Signaling in Tumor Stroma
Zhang, Y., Coleman, M., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13123070 · Cited by 39
Blocking Autophagy in Cancer-Associated Fibroblasts Supports Chemotherapy of Pancreatic Cancer Cells
Zhang, X., Schönrogge, M., Eichberg, J., Wendt, E. H. U., Kumstel, S., Stenzel, J., Lindner, T., Jaster, R., Krause, B. J., Vollmar, B., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00590 · Cited by 31
Cancer-Associated Fibroblast Proteins as Potential Targets against Colorectal Cancers
Shah, R., Johnson, K. A., Lippert, A. E. L., Kraus, S. G., Emmerich, P. B., Pasch, C. A., Zhang, W., Matkowskyj, K. A., LeBeau, A. M., & Deming, D. A. (2024) · Cancers · doi:10.3390/cancers16183158 · Cited by 18
Vidimar, V., Park, M., Stubbs, C. K., Ingram, N. K., Qiang, W., Zhang, S., Gursel, D., Melnyk, R. A., & Satchell, K. J. F. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0550 · Cited by 10
Current Status of Research on Losartan in Tumour Therapy
Wang, H., Yuan, S., & Wang, H. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70985 · Cited by 11
Brunel, A., Samain, R., Neuzillet, C., & Bousquet, C. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.06.09 · Cited by 5
Liang, C.-H., Ye, H., Xu, H., Fang, C., Lian, J.-P., Chen, Y.-Q., Wang, W.-T., & He, B. (2026) · Advanced Biotechnology · doi:10.1007/s44307-026-00141-8
Metadata
- Authors
- Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., De Jesus-Acosta, A., Sharma, P., Heidari, P., Mahmood, U., Chin, L., Moses, H. L., Weaver, V. M., Maitra, A., Allison, J. P., LeBleu, V. S., & Kalluri, R.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of California, San Francisco (US)
- Vanderbilt University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Kalluri, Raghu
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 25
- Issue
- 6
- Pages
- 719-734
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4180632
- OpenAlex
- W2088110734
- Cited by
- 2,681
- References
- 59
- Citations by year
- 2026: 248 · 2025: 215 · 2024: 232 · 2023: 245 · 2022: 309 · 2021: 280 · 2020: 256 · 2019: 185 · 2018: 187 · 2017: 170 · 2016: 168 · 2015: 143 · 2014: 43
- FWCI
- 84.54
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-12-14)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (144809)
- Oncosuisse
- National Institutes of Health
- National Cancer Institute (U01CA151925, P50CA127003, CA163191, R01CA113669, R01CA155370, CA 155370, UO1 CA151925, U54CA163191, R01CA125550, P30CA016672)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK81976, R01DK081576, DK-55001, R01DK055001)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- pancreatic ductal adenocarcinoma, cancer-associated fibroblasts, myofibroblasts, tumor stroma, fibrosis, alpha-smooth muscle actin, pancreatic intraepithelial neoplasia, tumor hypoxia, epithelial-mesenchymal transition, cancer stem cells, regulatory T cells, immunosuppression, gemcitabine resistance, tumor progression, patient survival
- MeSH terms
- Animals, Disease Models, Animal, Fibroblasts, Fibrosis, Humans, Immune Tolerance, Mice, Transgenic, Pancreatic Neoplasms, Survival Analysis, Carcinoma, Pancreatic Ductal, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
